AMCP Nexus in focus: Exploring Primes GLP-1 research in depth Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s Prior to the release of Prime Therapeutics (Prime) latest cost-of-care data from its ongoing real-world research on glucagon-like peptide-1 (GLP-1) agonist drugs, Prime researchers presented findings from the Year-2 adherence and persistence study as a research poster and an education session at Academy of Managed Care Pharmacy (AMCP) Nexus 2024 in Las Vegas, Nevada
It is a daily ritual that thousands of Indians have made part of their skincare routine
Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus
However, the presence of side effects doesn't determine weight loss successmany patients achieve excellent results with minimal nausea from day one
Although NAC co-exposure was not able to compensate for THC-induced GABA reductions, it normalized relative DA content, spontaneous EPSCs frequency, gamma power and behavioural abnormalities, underscoring the relevance of excitation/inhibition balance and its sensitivity to oxidative stress in these phenomena
medical providers and access to todays most trusted wellness treatments
